Plain-English translation of NCT04715191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of immunotherapy called CARE T cells for children with solid tumors that contain a protein called GPC3. Researchers take a small amount of blood from the patient, grow and genetically engineer their own T cells (immune cells) in the laboratory to recognize and attack cancer cells, and then infuse these modified cells back into the patient's body. The goal is to help the patient's own immune system fight the cancer more effectively.
Many children with solid tumors like liver cancer, rhabdomyosarcoma, and Wilms tumor do not respond well to standard treatments or their cancer returns after treatment. This trial exists to see if training a patient's own immune cells to target cancer cells offers a new option for children whose tumors have not been cured by conventional therapy.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will collect a small sample of your blood to grow and modify your immune cells in the laboratory over several weeks. Once the cells are ready, you will receive chemotherapy for 3 days to make room for the new cells to work, and then your modified cells will be thawed and infused into your body over about 5–10 minutes. You will need close follow-up care and monitoring to watch how your body responds to the treatment.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States